Lexicon's once-rejected diabetes drug is questioned again by FDA ahead of adcomm
The FDA is raising repeat safety and efficacy questions ahead of an advisory committee meeting on Thursday for Lexicon Pharmaceuticals’ SGLT2 inhibitor sotagliflozin, which the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
